drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous gene-engineered CAR T cells)
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting STEAP1 on prostate cancer cells; CAR engagement activates T-cell cytotoxicity and cytokine signaling against STEAP1-positive tumor cells.
nci_thesaurus_concept_id
C202957
nci_thesaurus_preferred_term
Anti-STEAP1 CAR T-cells
nci_thesaurus_definition
A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) six transmembrane epithelial antigen of the prostate 1 (STEAP1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-STEAP1 CAR T-cells recognize and bind to STEAP1-expressing tumor cells, thereby inducing selective toxicity in STEAP1-expressing tumor cells. STEAP1 is overexpressed in a variety of cancer cell types.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a CAR that binds STEAP1 on tumor cells; CAR engagement activates T-cell signaling, cytokine release, and cytotoxic granule-mediated killing of STEAP1-positive cancer cells.
drug_name
Anti-STEAP1 CAR T-cells
nct_id_drug_ref
NCT06236139